bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: J J M A M F J
2018: D N O S A J

  New Heart Failure Device Is Approved

By Scott Roberts

THURSDAY, March 21, 2019 (HealthDay News) -- The Optimizer Smart System has been approved by the U.S. Food and Drug Administration for people with chronic, moderate-to-severe heart failure who are not candidates for other heart failure remedies.

"Patients with moderate-to-severe chronic heart failure have limited treatment options. And for those who are unable to be treated due to underlying conditions or who have not responded to available treatments, their quality of life may be impacted, with limits on the types of physical activities they can do," said Dr. Bram Zuckerman, director of the agency's Division of Cardiovascular Devices.

Some 5.7 million people in the United States have heart failure, which occurs when the heart cannot pump enough blood. The prime causes are conditions that damage the heart, such as high blood pressure and diabetes, the FDA said Thursday in a news release.

The new system includes an implantable pulse generator, battery charger programmer and software. The pulse generator is implanted under the skin in the upper left or right area of the chest and is connected to three leads that are implanted in the heart. After the device is implanted, it delivers electrical impulses to the heart to help improve the organ's pumping capability.

The device was evaluated in clinical studies involving 389 people with moderate-to-severe heart failure. Those given the implant showed improvements in the distance they were able to walk and on standard assessments to measure heart failure symptoms, the FDA said.

Candidates for the system should have a regular heart rhythm, not be eligible for cardiac resynchronization therapy and have a left ventricular ejection fraction (the total amount of blood pumped out in each heartbeat) of 25 to 45 percent, which is below the normal ejection fraction of 55 to 75 percent.

Potential complications include infection, bleeding, worsening heart failure and fracture of the leads implanted in the heart.

The device is produced by Impulse Dynamics, based in Mt. Laurel, NJ.

More information

To learn more, visit the FDA.

Copyright © 2019 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=744116

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Heart
Heart Failure, Congestive
Equipment and Supplies
Blood
Therapeutics
Pulse
Infection
Motor Activity
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact